Blood-Based Biomarkers for Improved Characterization of Traumatic Brain Injury: Recommendations from the 2024 National Institute for Neurological Disorders and Stroke Traumatic Brain Injury Classification and Nomenclature Initiative Blood-Based Biomarkers Working Group
Top Cited Papers
Open Access
- 9 July 2025
- journal article
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 42 (13-14) , 1065-1085
Abstract
A 2022 report by the National Academies of Sciences, Engineering, and Medicine called for a Traumatic Brain Injury (TBI) Classification Workshop by the National Institutes of Health (NIH) to develop a more precise, evidence-based classification system. The workshop aimed to revise the Glasgow Coma Scale-based system by incorporating neuroimaging and validated blood biomarker tests. In December 2022, the National Institute for Neurological Disorders and Stroke formed six working groups of TBI experts to make recommendations for this revision. This report presents the findings and recommendations from the blood-based biomarker (BBM) working group, including feedback from the workshop and subsequent public review. The application of BBMs in a TBI classification system has potential to allow for a more adaptable and nuanced approach to triage, diagnosis, prognosis, and treatment. Current evidence supports the use of glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1, and S100B calcium-binding protein (S100B) to assist in reclassification of TBI at acute time points (0–24 h) primarily in emergency department settings, while neurofilament light chain (NfL), GFAP, and S100B have utility at subacute time points (1–30 days) in-hospital and intensive care unit settings. Blood levels of these biomarkers reflect the extent of structural brain injury in TBI and may be useful for describing the extent of structural brain injury in a classification system. While there is insufficient evidence to support a role for BBMs at chronic time points (>30 days), emerging evidence suggests that NfL and phosphorylated tau may have a potential future role in this regard. For inclusion in a revised TBI classification system, BBM assays must have appropriate age- and sex-specific reference ranges, be harmonized across platforms, and achieve high analytical precision, including accuracy, linearity, detection limits, selectivity, recovery, reproducibility, and stability. Improving transparency in BBM assay development can be achieved through large-scale data sharing of methods and results. Future research should focus on methods for promoting clinical adoption of BBM results, correlating BBMs with advanced neuroimaging, and on discovering new biomarkers for improved diagnosis and prognosis.Keywords
This publication has 141 references indexed in Scilit:
- Diagnostic Performance of GFAP, UCH-L1, and MAP-2 Within 30 and 60 Minutes of Traumatic Brain InjuryJAMA Network Open, 2024
- Evaluation of Glial and Neuronal Blood Biomarkers Compared With Clinical Decision Rules in Assessing the Need for Computed Tomography in Patients With Mild Traumatic Brain InjuryJAMA Network Open, 2022
- Assessment of Blood Biomarker Profile After Acute Concussion During Combative Training Among US Military CadetsJAMA Network Open, 2021
- A Prospective Study of Acute Blood‐Based Biomarkers for Sport‐Related ConcussionAnnals of Neurology, 2020
- Association of Blood Biomarkers With Acute Sport-Related Concussion in Collegiate AthletesJAMA Network Open, 2020
- Intracellular transport and regulation of transcytosis across the blood–brain barrierCellular and Molecular Life Sciences, 2018
- Assessment of Follow-up Care After Emergency Department Presentation for Mild Traumatic Brain Injury and ConcussionJAMA Network Open, 2018
- Extracellular matrix and traumatic brain injuryJournal of Neuroscience Research, 2018
- Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain InjuryJAMA Neurology, 2016
- Blood Biomarkers for Brain Injury in Concussed Professional Ice Hockey PlayersJAMA Neurology, 2014